United Therapeutics (NASDAQ:UTHR) Price Target Raised to $400.00

United Therapeutics (NASDAQ:UTHR) had its price objective boosted by TD Cowen from $350.00 to $400.00 in a research note published on Monday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other equities analysts have also issued reports on UTHR. Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and increased their price objective for the stock from $310.00 to $321.00 in a report on Thursday, July 11th. HC Wainwright reissued a “buy” rating and issued a $400.00 price target on shares of United Therapeutics in a research note on Thursday, August 1st. Wells Fargo & Company lifted their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the company an “overweight” rating in a research note on Tuesday, August 20th. UBS Group increased their target price on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research report on Monday, July 8th. Finally, LADENBURG THALM/SH SH downgraded shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, three have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $361.33.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $350.19 on Monday. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.35 and a quick ratio of 4.18. The firm has a market capitalization of $15.53 billion, a PE ratio of 16.56, a P/E/G ratio of 1.35 and a beta of 0.57. United Therapeutics has a 1-year low of $208.62 and a 1-year high of $377.03. The business’s fifty day moving average price is $353.45 and its two-hundred day moving average price is $311.48.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm had revenue of $714.90 million during the quarter, compared to analyst estimates of $691.87 million. During the same period last year, the business earned $5.24 EPS. The firm’s revenue was up 19.8% on a year-over-year basis. On average, research analysts expect that United Therapeutics will post 24.72 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 7,782 shares of the firm’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $366.99, for a total transaction of $2,855,916.18. Following the completion of the sale, the chief financial officer now directly owns 6,426 shares of the company’s stock, valued at $2,358,277.74. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, CFO James Edgemond sold 7,782 shares of the company’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $366.99, for a total transaction of $2,855,916.18. Following the completion of the sale, the chief financial officer now directly owns 6,426 shares of the company’s stock, valued at $2,358,277.74. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 3,600 shares of the stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $324.73, for a total value of $1,169,028.00. Following the completion of the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $42,214.90. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 102,812 shares of company stock valued at $35,251,926. Corporate insiders own 12.50% of the company’s stock.

Institutional Investors Weigh In On United Therapeutics

Hedge funds have recently made changes to their positions in the company. ClariVest Asset Management LLC lifted its stake in United Therapeutics by 120.0% in the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 42 shares in the last quarter. V Square Quantitative Management LLC purchased a new position in United Therapeutics during the second quarter valued at approximately $30,000. Innealta Capital LLC acquired a new position in United Therapeutics in the 2nd quarter valued at approximately $33,000. USA Financial Formulas purchased a new stake in United Therapeutics in the 3rd quarter worth approximately $33,000. Finally, Benjamin F. Edwards & Company Inc. boosted its stake in shares of United Therapeutics by 63.6% during the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock valued at $69,000 after buying an additional 117 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.